Synthesis and Evaluation of in vitro Antiplatelet Aggregation Activities of 2-Methoxy-5-Aminobenzamides

Author(s): Lili Liu, Xiujie Liu*, Guangling Chen, Kai Qiu.

Journal Name: Letters in Drug Design & Discovery

Volume 16 , Issue 9 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objective: According to the principles of drug design, the structures of picotamide and betrixaban were combined to design novel series of 2-methoxy-5-aminobenzamides. A total of twenty new compounds 1a-1t have been synthesized and evaluated for their antiplatelet aggregation activities in vitro.

Methods: In the structural design of target compounds 1a-1t, the betrixaban was retained group characteristics and the picotamide was retained its 1, 3, 4-substitution position. With 2-methoxybenzoic acid as starting material, compounds 1a-1t were synthesized after 5 steps of nitration, acylation, ammoniation, reduction and secondary ammoniation. And their antiplatelet aggregation activities in vitro were assessed by the Born test with ADP, arachidonic acid and collagen as inducing agents, respectively, and with aspirin and picotamide as two reference drugs.

Results: The compound 1f (46.14%±0.07) had the highest activity for ADP and its IC50 value was 0.17 µM, far better than the two control drugs aspirin (0.44 µM) and picotamide (0.47 µM). The IC50 value of four compounds 1i (0.24 µM), 1j (0.22 µM), 1r (0.25 µM) and 1t (0.24 µM), displayed higher antiplatelet activities in vitro for AA than aspirin (0.43 µM) and picotamide (0.34 µM). Evaluation of cytotoxicity activity of the compounds against L929 cells line revealed that at lower concentration of 10 µmol·L-1, compound 1p had lower effect on L929 cells, and its cell survival rate (88.24%±4.16) was higher than that (82.35%±4.16) of picotamide.

Conclusion: Novel series of 2-methoxy-5-aminobenzamides has shown higher in vitro antiplatelet activities and lower effect on L929 cells at lower concentration.

Keywords: Drug design, 2-methoxy-5-aminobenzamides, picotamide, betrixaban, structural modification, antiplatelet aggregation activities.

[1]
Lee, S.H.; Lee, W.; Bae, J.S.; Ma, E. Synthesis and in vitro and in vivo Anticoagulant and Antiplatelet Activities of Amidino- and Non-Amidinobenzamides. Molecules, 2016, 21(5), 676.
[2]
Mackman, N. Triggers, targets and treatments for thrombosis. Nature, 2008, 451(7181), 914-918.
[3]
Tian, Z. Clinical study on antiplatelet aggregation of picotamide. . Thesis, Jilin University: China, 2004.
[4]
Li, X. Structure Design and Synthesis of 4-ethoxy-1,3- Benzenedisulfonamide Derivatives and Anti-platelet Aggregation Activity in vitro., Thesis, Tianjin University: China,. 2016.
[5]
Liu, X.J.; Zhang, F.X.; Zhang, L.G.; Zhang, J.; Li, G.Z.; Wang, B.J.; Shao, Y.L.; Fang, L.; Cheng, M.S. Synthesis of the derivatives of picotamide and the inhibition of blood platelet aggregation. Chin. J. Med. Chem. , 2005, 15(6), 332-335.
[6]
Liu, X.J.; Shao, Y.L.; Wang, C.Q.; He, X.; Si, H.Q.; Wang, S.J. Synthesis of picotamide analogues and their platelet aggregation inhibitory activities. Chin. J. Med. Chem., 2007, 17(6), 354-357.
[7]
Zhao, D.Y.; Meng, J.; Wang, T.T.; Deng, N.; Liu, X.J. Synthesis and in vitro anti-platelet aggregation activity of 4-methoxy-1,3-benzenediolate compounds. J. China Pharm. Univ., 2012, 43(1), 21-24.
[8]
Wang, T.T.; Liu, X.J.; Shao, Y.L.; Si, H.Q.; Hu, T.; Zhang, J.; Shi, X.X. Synthesis and in vitro activities on anti-platelet aggregation of N,N′-di(2-substituted-phenyl)-4-methoxybenzene-1,3- disulfonamides. Chin. J. Med. Chem., 2012, 2, 99-103.
[9]
Lin, Y.B.; Li, X.; Shi, T.E.; Li, G.L.; Liu, X.J. Synthesis and antiplatelet aggregation activity of 4-ethoxy-N, N′- di(substituted phenyl)amides. Chin. J. Med. Chem., 2015, 5, 355-360.
[10]
Deng, Q.S.; Zhang, Q.X.; Wang, C.Q.; Liu, X.J. Synthesis and in vitro antiplatelet aggregation activity of N1,N3-dibenzyl-4-methoxy-1,3-benzenedisulfonamide compounds. Chin. J. Med. Chem., 2017, 5, 355-359.
[11]
Zhao, H.; Chu, Q.Q.; Wang, H.; Shang, Z.H. Synthetic process of Betrixaban. Chin. J. New Drugs, 2014, 24, 2902-2904.
[12]
Hu, T.T.; Zhu, H.; Lin, M.Q.; Song, H.T. Research progress of novel oral anticoagulants in the treatment of non-valvular atrial fibrillation. China Pharm., 2016, 27(8), 1139-1142.
[13]
Wang, D.; Zhang, J.M. Research advances in the prevention of atrial fibrillation-related stroke with novel oral anticoagulants. J. Pract. Cardiol. Brain Pulmon. Dis., 2015, 8, 1-4.
[14]
Zhang, J.Z. An overview of new drugs approved by the FDA in June 2017. Sh. Med., 2017, 38(15), 95-95.
[15]
Barbosa, Jr F.; Sertorio, J.T.; Gerlach, R.F.; Tanus-Santos, J.E. Clinical evidence for lead-induced inhibition of nitric oxide formation. Arch. Toxicol., 2006, 80(12), 811-816.
[16]
BORN. G.V.R. Aggregation of blood platelets byadenosine diphosphate and its reveasal. Nature, 1962, 194(4832), 927-929.
[17]
Guo, P.; Gu, W.X.; Chen, Q.X.; Lu, H.G.; Han, X.Q.; Li, W.; Gao, H. Dual functionalized amino poly (glycerol methacrylate) with guanidine and schiff-base linked imidazole for enhanced gene transfection and minimized cytotoxicity. J. Mater. Chem. B , 2015, 3(34), 6911-6918.
[18]
Liu, X.J.; Wang, C.Q.; Meng, J.; Shi, X.X.; Yan, Y.N.; Liu, X.G. Design, synthesis and biological evaluation of 4-methoxy diaryl isophthalates as antiplatelet agents. Med. Chem. Res., 2017, 1, 1-9.
[19]
Xu, S.Y.; Bian, R.L.; Chen, X. Pharmacological experimental methods, 2rd ed.; People’s medical Publishing House, Beijing. , 1991, pp. 14381-442.
[20]
Xiong, J.W.; Xiao, H.; Zhang, Z.X. An experimental research on different detection conditions between MTT and CCK-8. Acta. Laser. Biol. Sin., 2007, 16(5), 559-562.
[21]
Li, C.; Yang, Y.W.; Liang, Z.; Wu, G.; Gao, H. Post-modification of poly(glycidyl methacrylate)s with alkyl amine and isothiocyanate for effective pDNA delivery. Polym. Chem., 2013, 4(16), 4366-4374.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 9
Year: 2019
Page: [1040 - 1050]
Pages: 11
DOI: 10.2174/1570180816666181128105044

Article Metrics

PDF: 24
HTML: 2
EPUB: 1
PRC: 1